Janus Henderson Group
CERE

Janus Henderson Group’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Janus Henderson Group’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-293,385
Closed -$12M – 2574
2024
Q2 		$12M Buy
293,385
+256,143
+688% +$10.7M 0.01% 652
2024
Q1 		$1.57M Sell
37,242
-18
-0% -$756 ﹤0.01% 1398
2023
Q4 		$1.58M Buy
37,260
+9,399
+34% +$270K ﹤0.01% 1366
2023
Q3 		$608K Sell
27,861
-956,134
-97% -$23.9M ﹤0.01% 1832
2023
Q2 		$31.3M Sell
983,995
-84,563
-8% -$2.6M 0.02% 487
2023
Q1 		$26.1M Sell
1,068,558
-82,763
-7% -$2.43M 0.02% 511
2022
Q4 		$36.3M Sell
1,151,321
-231,639
-17% -$6.54M 0.03% 442
2022
Q3 		$39.1M Buy
1,382,960
+1,369,554
+10,216% +$40.8M 0.03% 412
2022
Q2 		$355K Buy
13,406
+3,198
+31% +$90.8K ﹤0.01% 1978
2022
Q1 		$358K Buy
+10,208
New +$298K ﹤0.01% 2113

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Janus Henderson Group's CERE Position: Q3 2024 in Review

Janus Henderson Group sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 293,385 shares — an estimated $12M sold.

Janus Henderson Group first reported a position in CERE in Q1 2022 and held it in 10 quarters. The position peaked at $39.1M in Q3 2022. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Janus Henderson Group reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Janus Henderson Group sold 293,385 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $12M.
  • Janus Henderson Group first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2022 and held it in 10 quarters.
  • Janus Henderson Group's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $39.1M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Janus Henderson Group's 13F filing for Q3 2024, filed 14 Nov 2024.